Intellectual Property

ReGenX AAV Vector Technology is protected by an intellectual property estate that includes 19 issued U.S. patents and 20 foreign patents, as well as more than 50 patent applications pending throughout the world’s major markets for biotechnology products – U.S., Europe, Japan. We believe that no other company possesses a portfolio of such broad and exclusive rights to the patents and patent applications required for the development of AAV vector based therapeutics, making us the leader in the field. Our intellectual property includes a wide range of important biology, genetic material delivery, and therapeutic target patents, the most fundamental of which provides us with exclusive rights to vectors derived from novel serotypes of AAV, including AAV7, AAV8, and AAV9.

These AAV vectors are particularly well suited for the development of therapeutic product candidates based on characteristics of these novel AAV serotypes and ReGenX believes its intellectual property is important in providing competitive advantage and product exclusivity for its mission to develop novel AAV vector based therapeutics.